Investment Announcements - Jincheng intends to invest approximately $231 million in the Alacran copper-gold-silver mine project, following the acquisition of a 5% stake in CMH Colombia S.A.S., which will allow it to hold a 55% stake and control the project development [3] - Huasheng Technology's subsidiary plans to sell a 5.4019% stake in Shanghai Lingkai Technology Co., Ltd. for 200 million yuan, resulting in the subsidiary no longer holding shares in the company [4] - China Merchants Bank plans to invest 15 billion yuan to establish a wholly-owned financial asset investment company, which will enhance its integrated operations and service capabilities [5] Performance Reports - Huahong's Q1 revenue reached 3.913 billion yuan, a year-on-year increase of 18.66%, while net profit dropped by 89.73% to 22.76 million yuan, indicating challenges in the semiconductor industry due to international and policy changes [7] - King Long Automobile reported a production of 4,361 buses in April, a decrease of 5.79% year-on-year, with sales of 3,611 buses, down 3.91% [8] - Zhengbang Technology's April pig sales reached 609,800 heads, with revenue of 738 million yuan, showing a significant year-on-year increase of 174.29% [9] - Sunac China achieved a contract sales amount of approximately 1.1 billion yuan in April, with a cumulative total of 11.2 billion yuan by the end of April [11] - *ST Aonong reported a pig sales volume of 132,800 heads in April, a year-on-year decrease of 14.42% [12] Major Contracts - Pinggao Electric won contracts totaling approximately 1.751 billion yuan from the State Grid, representing 14.12% of its 2024 revenue [14] - State Grid Information Technology's subsidiaries secured contracts worth 477 million yuan, positively impacting future performance [15] - Dongfang Tower won a procurement project from the State Grid worth about 100 million yuan, accounting for 2.39% of its 2024 revenue [16] - Jiaojian Co. won a construction project worth approximately 704 million yuan, with a project duration of 870 days, representing 8.43% of its 2024 revenue [17] Shareholding Changes - Ruihua Tai's shareholder plans to reduce holdings by up to 1% of the company's shares [19] - *ST Gengxing's controlling shareholder intends to increase holdings between 30 million and 60 million yuan [20] - Lexin Technology's shareholder plans to reduce holdings by up to 1.2032% of the company's shares [22] Share Buybacks - Sichuan Meifeng plans to repurchase shares worth between 50 million and 70 million yuan, with a maximum repurchase price of 10.07 yuan per share [24]

Group 1 - The core point of the article is that Huasheng Technology (000790) announced the transfer of 5.4019% shares of Shanghai Lingkai held by its subsidiary Xingrui Pharmaceutical for 200 million yuan, after which Xingrui Pharmaceutical will no longer hold any shares in Shanghai Lingkai [1] Group 2 - The transaction indicates a strategic decision by Huasheng Technology to divest its stake in Shanghai Lingkai, potentially reallocating resources or focusing on other investments [1] - The completion of this transaction marks a significant change in the ownership structure of Shanghai Lingkai, as Xingrui Pharmaceutical exits its investment [1] - The financial implications of this transfer could affect Huasheng Technology's balance sheet and future investment strategies [1]

证券代码：000790 证券简称：华神科技 公告编号：2025-017 成都华神科技集团股份有限公司 关于子公司出售参股公司股权的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、交易概述 成都华神科技集团股份有限公司（以下简称"公司"）于 2025 年 5 月 6 日召开第十 三届董事会第二十一次会议，审议通过了《关于子公司出售参股公司股权的议案》，同意 公司子公司海南华神星瑞药业科技有限公司（以下简称"星瑞药业"）将持有的上海凌凯科 技股份有限公司（以下简称"上海凌凯"）5.4019%股份以人民币 2 亿元转让给陆茜，本次交 易完成后，星瑞药业不再持有上海凌凯股份。 2022 年 9 月 29 日公司召开第十二届董事会第二十四次会议，审议通过了《关于全资 子公司对外投资的议案》，具体内容详见公司于 2022 年 9 月 30 日在巨潮资讯网披露的《关 于全资子公司对外投资的公告》（公告编号 2022-051）。 2024 年 5 月 16 日公司召开第十三届董事会第十二次会议，审议通过了《关于签署< 补充协议>及<股东特殊权利之终止协议>的议案》， ...

证券代码：000790 证券简称：华神科技 公告编号：2025-016 公司子公司海南华神星瑞药业科技有限公司（以下简称"星瑞药业"）拟将 持有的上海凌凯科技股份有限公司（以下简称"上海凌凯"）5.4019%股份，以人 民币 2 亿元转让给陆茜，本次交易完成后，星瑞药业不再持有上海凌凯股份。 具体内容详见公司同日在巨潮资讯网披露的相关公告。 表决结果：同意 9 票，反对 0 票，弃权 0 票。 三、备查文件 成都华神科技集团股份有限公司 第十三届董事会第二十一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 成都华神科技集团股份有限公司（简称"公司"）第十三届董事会第二十一 次会议于2025年5月6日以现场与通讯表决相结合的方式在公司会议室召开。经 与全体董事沟通确认，全体董事同意豁免本次董事会会议的提前通知期限，会 议通知于2025年5月6日以现场及电话方式送达全体董事。本次会议应出席董事9 人，实际出席董事9人。会议由公司董事长黄明良先生主持，公司监事、高级管 理人员列席了会议。本次会议的召集、召开符合有关法律、行政法 ...

Core Viewpoint - The National Medical Products Administration (NMPA) has approved Chengdu Huasheng Technology Group Co., Ltd.'s Sanqi Tongshu Capsules as the first secondary protected traditional Chinese medicine variety, with a protection period of seven years starting from the announcement date [1][2]. Product Information - Product Name: Sanqi Tongshu Capsules - Dosage Form: Capsule - Specification: 0.2g per capsule - Indications: The product is indicated for promoting blood circulation, alleviating blood stasis, improving cerebral infarction and ischemic dysfunction, restoring ischemic brain metabolism abnormalities, preventing platelet aggregation, and improving microcirculation, primarily used for cerebrovascular embolic diseases such as stroke and hemiplegia [1][3]. Product Overview - Sanqi Tongshu Capsules are derived from the active components of the Sanqi herb, specifically the saponins, and are recognized as a new generation of Sanqi preparations. The product has multiple effects, including preventing thrombosis and promoting nerve function recovery, and has been included in various clinical guidelines for the treatment of cerebrovascular diseases. The product has received several awards for its technological advancements and its active ingredient has been recognized in international pharmacopoeias [3]. Impact on the Company - The approval of Sanqi Tongshu Capsules as a secondary protected variety enhances market protection and is expected to improve the product's core competitiveness, positively impacting the company's operations. However, the short-term impact on the company's financial performance is expected to be limited due to uncertainties in the pharmaceutical industry and market environment [4].

Policy Developments - Hainan Province has released a plan to enhance the quality of generic drugs, supporting the expedited registration and market entry of first generic products, particularly those that are urgently needed in clinics or have high prices or supply shortages [1] - The plan includes strengthening supervision of entrusted production and supporting consistency evaluations for the quality and efficacy of generic drugs, which will improve overall drug quality and ensure public safety [1] Drug and Device Approvals - Huasheng Technology's Sanqi Tongshu Capsules have been approved as the first secondary protected traditional Chinese medicine by the National Medical Products Administration, enhancing the company's core competitiveness in treating cardiovascular diseases [2] - United Imaging Healthcare's digital subtraction angiography system (DSA) uAngioAVIVA has received FDA approval, marking it as the first and only domestic DSA device allowed in the U.S. market [3] - Warner Pharmaceuticals has received a listing approval notice for potassium sulfate, which will enrich the company's product line and enhance its core competitiveness [4] - Xinhua Medical has obtained a Class II medical device registration certificate for its multi-chamber cleaning and disinfection device, which significantly reduces processing time compared to fully automatic devices [5] Financial Reports - Kelun Pharmaceutical reported a 29.42% year-on-year decline in revenue for Q1 2025, totaling 4.389 billion yuan, with a net profit decrease of 43.07% to 584 million yuan [6][7] - AstraZeneca's Q1 2025 revenue reached $13.588 billion, a 10% increase year-on-year, driven by double-digit growth in oncology and biopharmaceuticals [8] Capital Market Activities - Koser Medical Technology has completed nearly 100 million yuan in B+ round financing, which will be used for core product development and global market expansion [9] - Xellar Biosystems has secured several million yuan in strategic investment from XtalPi, aimed at accelerating the development of its organ-on-chip technology and expanding international collaborations [10] Industry Developments - Chen Yuqing has been appointed as the new chairman of Fosun Pharma, succeeding Wu Yifang, and will oversee the company's strategic development and organizational growth [11] - Merck has announced a $1 billion investment to build a production facility in Wilmington, Delaware, aimed at producing the next generation of biopharmaceuticals, including Keytruda [12] - Prilenia has entered a collaboration agreement with Ferrer for the oral sigma-1 receptor agonist Pridopidine, with a total deal value of up to €500 million [13] - Junshi Biosciences has signed a licensing agreement with Sandoz for its HLX13 monoclonal antibody, receiving an upfront payment of $31 million and potential milestone payments totaling $1.6 billion [14] Public Sentiment Alerts - Medici has announced that major shareholder Chen Jianhuang plans to reduce his stake by up to 2.23% between May 26 and August 25, 2025, due to personal funding needs [15]

剂型：胶囊剂 规格：每粒装0.2g 证券代码：000790 证券简称：华神科技 公告编号：2025-015 成都华神科技集团股份有限公司 关于三七通舒胶囊获批国家首家中药二级保护品种的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 近日，国家药品监督管理局（以下简称"国家药监局"）网站发布《中药保 护品种公告（第25号）（2025年第45号）》，批准成都华神科技集团股份有限 公司（以下简称"公司"）分公司成都华神科技集团股份有限公司制药厂（以下 简称"集团制药厂"）的三七通舒胶囊为首家中药二级保护品种，保护品种编号 为：ZYB2072025008，保护期限自公告日起七年。现将相关情况公告如下： 一、药品基本信息 药 品 名 称：三七通舒胶囊 功能主治：活血化瘀，活络通脉，改善脑梗塞、脑缺血功能障碍，恢复缺 血性脑代谢异常,抗血小板聚集，防止血栓形成，改善微循环，降低全血黏度， 增加颈动脉血流量，主要用于心脑血管栓塞性病症，主治中风、半身不遂、口 舌歪斜、言语謇涩、偏身麻木。 保 护 品 种 号：ZYB2072025008 审 批 结 论：根据《中药品种保 ...

Financial Performance - The company reported a basic earnings per share of -0.0100 yuan for 2024, a decrease of 125% compared to 0.0400 yuan in 2023 [1] - The net profit for 2024 was -0.07 billion yuan, down 125% from 0.28 billion yuan in 2023 [1] - Operating revenue decreased by 13.86% to 8.64 billion yuan in 2024 from 10.03 billion yuan in 2023 [1] - The return on equity (ROE) fell to -0.65% in 2024 from 2.72% in 2023, a decline of 123.9% [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 15,777.3 million shares, accounting for 25.34% of the circulating shares, with a decrease of 529.52 million shares from the previous period [1] - Sichuan Huashen Group Co., Ltd. remains the largest shareholder with 11,143.13 million shares, representing 17.89% of total share capital [2] - New entrants among the top shareholders include Tao Wentao with 300.00 million shares and Li Ting with 276.01 million shares [2] - Notable exits from the top ten shareholders include Huang Laifeng, Ding Shugan, Huang Yizhong, and Yu Haoxin [2]

| 四川华信 (集团) 会计师事务所 地址:成都市洗面桥街 18 号金茂礼都南 28 楼 | | --- | | 电话:(028) 85560449 | | (特殊普通合伙) 传真:(028) 85560449 | | 邮编:610041 | | SI CHUAN HUA XIN (GROUP) CPA (LLP) 电邮: schxzhb@hxcpa.com.cn | 成都华神科技集团股份有限公司 2024 年度内部控制审计报告 川华信专(2025) 第 0575 号 目录: 1、内部控制审计报告 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn/ 成都华神科技集团股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求,我们审计了成 都华神科技集团股份有限公司(以下简称"贵公司"或"华神科技")2024年12月31日的 财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控制评价指引》 的规定,建立健全和有效实施内部控制,并评价其有效性是贵公司董事会的责任。 ...

| 四川华信 (集团)会计师事务所 地址:成都市洗面桥街 18 号金茂礼都南 28 楼 | | --- | | 电话:(028) 85560449 | | (特殊普通合伙) 传真:(028) 85560449 | | 邮编:610041 | | SI CHUAN HUA XIN (GROUP) CPA (LLP) 电邮: schxzhb@2hxcpa.com.cn | 成都华神科技集团股份有限公司 2024 年度非经营性资金占用及其他关联资金往来情况的专项说明 川华信专(2025) 第 0572 号 目录: 1、成都华神科技集团股份有限公司 2024年度非经营性资金占用及其他关联资 金往来情况的专项说明 2、成都华神科技集团股份有限公司 2024年度非经营性资金占用及其他关联资 金往来情况汇总表 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（hmx//scc.mof enx co 专项审核说明 成都华神科技集团股份有限公司 成都华神科技集团股份有限公司 2024 年度 非经营性资金占用及其他关联资金往来情况 的专项说明 川华信专(2025) 第 0572 号 成都华神科技集团股份有限公司全体股东: ...